B. Riley set a $6.00 price objective on Biomerica (NASDAQ:BMRA) in a research note issued to investors on Tuesday morning, TipRanks reports. The firm currently has a buy rating on the stock. B. Riley also issued estimates for Biomerica’s Q1 2020 earnings at ($0.06) EPS, Q2 2020 earnings at ($0.08) EPS, Q3 2020 earnings at ($0.06) EPS, FY2020 earnings at ($0.27) EPS and FY2022 earnings at $0.75 EPS.
Shares of NASDAQ:BMRA traded up $0.18 during trading on Tuesday, reaching $3.05. 24,500 shares of the company’s stock traded hands, compared to its average volume of 27,625. Biomerica has a 12 month low of $1.60 and a 12 month high of $3.78. The company has a 50 day moving average of $3.13 and a 200-day moving average of $2.67. The stock has a market capitalization of $28.91 million, a P/E ratio of -11.73 and a beta of 1.45.
Biomerica (NASDAQ:BMRA) last announced its quarterly earnings data on Friday, August 30th. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). Biomerica had a negative net margin of 46.01% and a negative return on equity of 58.31%. The business had revenue of $1.17 million during the quarter, compared to the consensus estimate of $1.36 million. On average, research analysts anticipate that Biomerica will post -0.33 EPS for the current year.
Biomerica Company Profile
Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.
See Also: P/E Growth (PEG)
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.